Sanofi Q3 Net Profit Rises on 14.3% Sales Growth, Lifts FY26 Outlook

Sanofi SA (SNY, SAN.PA) reported higher third-quarter net profit and raised its fiscal 2026 outlook, citing strong sales growth. Net income attributable to equity holders rose to 3.021 billion euros from 2.802 billion euros a year earlier, with basic earnings per share of 2.52 euros versus 2.30 euros. Business net income climbed to 4.255 billion euros from 3.547 billion euros, and business earnings per share were 3.55 euros compared with 2.91 euros. Net sales grew 14.3% at constant exchange rates to 14.444 billion euros. Dupixent sales rose 34.8% to 5.7 billion euros, and pharma launches increased 31.4%, driven by ALTUVIIIO, Ayvakit and Rezurock. Vaccine sales fell 6.6% on anticipated phasing in respiratory prevention. For fiscal 2026, Sanofi now expects business earnings per share to grow by a mid-teens percentage and sales by a low-teens percentage, both at constant exchange rates, upgrading its prior guidance of roughly 10% sales growth.